UK markets closed

Galapagos NV (GLPGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
54.250.00 (0.00%)
At close: 03:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close54.25
Open54.25
Bid0.00 x 0
Ask0.00 x 0
Day's range54.25 - 54.25
52-week range48.55 - 69.00
Volume20
Avg. volume1,251
Market cap3.638B
Beta (5Y monthly)0.31
PE ratio (TTM)N/A
EPS (TTM)-2.01
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Are Medical Stocks Lagging Galapagos (GLPG) This Year?

    Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

  • Globe Newswire

    Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

    Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s cutting-edge fully human antibody-based capabilities, providing a platform of next-generation CAR-Ts and bispecific antibodiesClinical validation of decentralized production platform with CD19 CAR-T in 2 Phase 1/2a studies in relapsed/refractory Non-Hodgkin’s-Lymphoma (rrNHL) and Chronic Lymphocytic Leukemia (rrCLL) ongoing, with topline resul

  • Globe Newswire

    Galapagos increases share capital through subscription right exercises

    Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 80,290 new ordinary shares on 20 June 2022, for a total capital increase (including issuance premium) of EUR 1,459,506.60. Pursuant to the subscription right exercise program for Galapagos’ executive committee, the members of the executive committee automatically are committed to exercise a minimu